ECMO Strikes Out in Patients with Acute Myocardial Infarction and Cardiogenic Shock

A major randomized trial showed no mortality difference with extracorporeal membrane oxygenation versus supportive care alone.

Despite great strides in managing acute myocardial infarction (AMI), 30-day mortality rates remain at 40% to 50% when cardiogenic shock complicates AMI (AMI-CS). Several percutaneous devices can provide substantial, temporary circulatory support to vital organs (about 3–5 liters/minute of blood flow). Given their relative safety and ease of insertion, short-term circulatory support with these devices has been hypothesized to offer potential benefit in patients with AMI-CS as cardiac function recovers.

To assess whether this approach improves survival, investigators randomized 420 patients (mean age, 63 years; 19% women) with AMI-CS who were undergoing planned coronary revascularization (almost all with percutaneous coronary intervention) to …

Reviewing Author

David J. Cohen, MD, MSc

Disclosures

Consultant/Advisory BoardMedtronic; Edwards Lifesciences; Abbott Vascular; Boston Scientific; St. Francis Hospital

Speaker’s BureauBoston Scientific; ZOLL Medical

Grant/Research SupportEdwards Lifesciences; Abbott Vascular; Boston Scientific; Corvia Medical; National Heart, Lung, and Blood Institute; Phillips, Inc.; St. Paul’s Hospital; V-Wave, Inc; ZOLL Medical; CathWorks, ANCORA

Editorial BoardsJACC; American Heart Journal; EuroIntervention; JSCAI; Structural Heart Journal

Leadership Positions in Professional SocietiesSociety of Thoracic Surgeons/American College of Cardiology TVT Registry (Co-Chair, Risk Model Development Committee); Cardiovascular Research Foundation (Co-Director, TCT Annual Meeting; Co-Director, New York Valves Annual Meeting)